SLNO
Soleno Therapeutics, Inc.$52.77+0.02 (+0.04%)Prev Close$52.75·MCap$2.73B·P/E232.71·Vol868.1K·Yield—
▲
Buys (12M)
0
$0.00
▼
Sells (12M)
9
$1.43M
◆
Net Activity
Net Seller
$1.43M
●
Active Insiders
6
last 12 mo
Over the past 12 months, insider activity at Soleno Therapeutics, Inc. (SLNO) has been exclusively selling, with 0 insider purchases totaling $0.00 and 9 insider sales totaling $1.43M. The most recent insider transaction was by Huang Michael F. (officer: Sr. VP of Clinical Development), who sold $200.4K worth of shares on Mar 31, 2026. Soleno Therapeutics, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $2.73B.
SLNO Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Mar 31, 2026 | Huang Michael F. | officer: Sr. VP of Clinical Development | Sell | 6,582 | $30.44 | $200.4K | 42,149 |
| Mar 31, 2026 | Manning Meredith | officer: Chief Commercial Officer | Sell | 7,522 | $30.44 | $229.0K | 67,165 |
| Dec 15, 2025 | Anish Bhatnagar | CHIEF EXECUTIVE OFFICER | Sell | 7,620 | $49.95 | $380.6K | 0 |
| Dec 15, 2025 | Huang Michael F. | Sr. VP of Clinical Development | Sell | 812 | $49.95 | $40.6K | 0 |
| Dec 15, 2025 | Mackaness James H | CHIEF FINANCIAL OFFICER | Sell | 2,013 | $49.95 | $100.5K | 0 |
| Dec 15, 2025 | Manning Meredith | Chief Commercial Officer | Sell | 1,922 | $49.95 | $96.0K | 0 |
| Dec 15, 2025 | Yen Kristen | SEE REMARKS | Sell | 904 | $49.95 | $45.2K | 0 |
| Jul 1, 2025 | Hirano Patricia C | SEE REMARKS | Sell | 3,830 | $82.76 | $317.0K | 0 |
| Jun 24, 2025 | Hirano Patricia C | SEE REMARKS | Sell | 266 | $84.25 | $22.4K | 0 |
| Apr 1, 2025 | Hirano Patricia C | SEE REMARKS | Sell | 3,782 | $70.11 | $265.2K | 0 |
| Mar 28, 2025 | Pauls Matthew | Director | Sell | 5,937 | $71.55 | $424.8K | 0 |
| Mar 27, 2025 | Anish Bhatnagar | CHIEF EXECUTIVE OFFICER | Sell | 699,095 | $67.62 | $47.27M1.3% OS | 0 |
| Mar 27, 2025 | Hirano Patricia C | SEE REMARKS | Sell | 156,315 | $68.51 | $10.71M | 0 |
| Mar 27, 2025 | Huang Michael F. | Sr. VP of Clinical Development | Sell | 14,583 | $69.51 | $1.01M | 0 |
| Mar 27, 2025 | Mackaness James H | CHIEF FINANCIAL OFFICER | Sell | 90,622 | $69.44 | $6.29M | 0 |
| Mar 27, 2025 | Manning Meredith | Chief Commercial Officer | Sell | 45,249 | $67.28 | $3.04M | 0 |
| Mar 27, 2025 | Yen Kristen | SEE REMARKS | Sell | 95,500 | $66.77 | $6.38M | 0 |
| Jan 6, 2025 | Anish Bhatnagar | CHIEF EXECUTIVE OFFICER | Sell | 21,091 | $45.78 | $965.5K | 709,476 |
| Jan 6, 2025 | Hirano Patricia C | SEE REMARKS | Sell | 3,030 | $45.78 | $138.7K | 107,485 |
| Jan 6, 2025 | Mackaness James H | CHIEF FINANCIAL OFFICER | Sell | 7,874 | $45.78 | $360.5K | 115,410 |
| Jan 6, 2025 | Yen Kristen | SEE REMARKS | Sell | 4,860 | $45.78 | $222.5K | 79,143 |
| Oct 3, 2024 | Anish Bhatnagar | CHIEF EXECUTIVE OFFICER | Sell | 21,633 | $49.43 | $1.07M | 721,773 |
| Oct 3, 2024 | Hirano Patricia C | SEE REMARKS | Sell | 3,108 | $49.43 | $153.6K | 109,251 |
| Oct 3, 2024 | Mackaness James H | CHIEF FINANCIAL OFFICER | Sell | 8,077 | $49.43 | $399.2K | 120,001 |
| Oct 3, 2024 | Yen Kristen | SEE REMARKS | Sell | 3,108 | $49.43 | $153.6K | 81,784 |
| Aug 30, 2024 | Anish Bhatnagar | CHIEF EXECUTIVE OFFICER | Sell | 115,004 | $47.43 | $5.45M | 825,928 |
| Aug 30, 2024 | Hirano Patricia C | SEE REMARKS | Sell | 10,705 | $47.43 | $507.7K | 119,928 |
| Aug 30, 2024 | Mackaness James H | CHIEF FINANCIAL OFFICER | Sell | 13,531 | $47.43 | $641.8K | 137,219 |
| Aug 30, 2024 | Yen Kristen | SEE REMARKS | Sell | 10,705 | $47.43 | $507.7K | 92,461 |
| Aug 29, 2024 | Vivo Opportunity, LLC | 10% Owner | Sell | 1,025,000 | $48.01 | $49.21M1.9% OS | 6,816,851 |
| Aug 7, 2024 | Anish Bhatnagar | CHIEF EXECUTIVE OFFICER | Sell | 127,344 | $45.60 | $5.81M | 950,745 |
| Aug 7, 2024 | Hirano Patricia C | SEE REMARKS | Sell | 11,009 | $45.60 | $502.0K | 130,920 |
| Aug 7, 2024 | Mackaness James H | CHIEF FINANCIAL OFFICER | Sell | 14,983 | $45.60 | $683.2K | 151,905 |
| Aug 7, 2024 | Yen Kristen | SEE REMARKS | Sell | 10,974 | $45.60 | $500.4K | 103,426 |
| Jul 3, 2024 | Anish Bhatnagar | CHIEF EXECUTIVE OFFICER | Sell | 19,256 | $41.54 | $799.8K | 148,592 |
| Jul 3, 2024 | Hirano Patricia C | SEE REMARKS | Sell | 2,170 | $41.54 | $90.1K | 50,451 |
| Jul 3, 2024 | Mackaness James H | CHIEF FINANCIAL OFFICER | Sell | 7,190 | $41.54 | $298.7K | 61,385 |
| Jul 3, 2024 | Yen Kristen | SEE REMARKS | Sell | 2,170 | $41.54 | $90.1K | 22,949 |
| May 1, 2024 | Vivo Opportunity, LLC | 10% Owner | Sell | 1,101,242 | $46.95 | $51.70M2.1% OS | 7,668,093 |
| Apr 3, 2024 | Anish Bhatnagar | CHIEF EXECUTIVE OFFICER | Sell | 18,980 | $41.34 | $784.6K | 160,387 |
| Apr 3, 2024 | Hirano Patricia C | SEE REMARKS | Sell | 2,218 | $41.34 | $91.7K | 50,924 |
| Apr 3, 2024 | Mackaness James H | CHIEF FINANCIAL OFFICER | Sell | 5,175 | $41.34 | $213.9K | 65,024 |
| Apr 3, 2024 | Yen Kristen | SEE REMARKS | Sell | 2,218 | $41.34 | $91.7K | 24,310 |
| Jan 29, 2024 | Anish Bhatnagar | CHIEF EXECUTIVE OFFICER | Sell | 2,527 | $48.30 | $122.1K | 171,770 |
| Jan 29, 2024 | Hirano Patricia C | SEE REMARKS | Sell | 832 | $48.30 | $40.2K | 43,142 |
| Jan 29, 2024 | Yen Kristen | SEE REMARKS | Sell | 397 | $48.30 | $19.2K | 25,640 |
| Dec 15, 2023 | Hirano Patricia C | See Remarks | Sell | 6,244 | $38.29 | $239.1K | 21,333 |
| Dec 14, 2023 | Yen Kristen | See Remarks | Sell | 37,829 | $37.34 | $1.41M | 18,321-67% |
| Dec 13, 2023 | Anish Bhatnagar | Chief Executive Officer | Sell | 93,408 | $35.67 | $3.33M | 66,500-58% |
| Dec 13, 2023 | Mackaness James H | Chief Financial Officer | Sell | 32,482 | $36.41 | $1.18M | 38,358-46% |
Showing 1–50 of 68
1 / 2
SLNO Insider Buying Activity
The following table shows recent insider purchases of Soleno Therapeutics, Inc. (SLNO) stock reported via SEC Form 4 filings.
No insider buying activity found for SLNO in the last 12 months.
SLNO Insider Selling Activity
The following table shows recent insider sales of Soleno Therapeutics, Inc. (SLNO) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Mar 31, 2026 | Huang Michael F. | officer: Sr. VP of Clinical Development | Sell | 6,582 | $30.44 | $200.4K | 42,149 |
| Mar 31, 2026 | Manning Meredith | officer: Chief Commercial Officer | Sell | 7,522 | $30.44 | $229.0K | 67,165 |
| Dec 15, 2025 | Anish Bhatnagar | CHIEF EXECUTIVE OFFICER | Sell | 7,620 | $49.95 | $380.6K | 0 |
| Dec 15, 2025 | Huang Michael F. | Sr. VP of Clinical Development | Sell | 812 | $49.95 | $40.6K | 0 |
| Dec 15, 2025 | Mackaness James H | CHIEF FINANCIAL OFFICER | Sell | 2,013 | $49.95 | $100.5K | 0 |
| Dec 15, 2025 | Manning Meredith | Chief Commercial Officer | Sell | 1,922 | $49.95 | $96.0K | 0 |
| Dec 15, 2025 | Yen Kristen | SEE REMARKS | Sell | 904 | $49.95 | $45.2K | 0 |
| Jul 1, 2025 | Hirano Patricia C | SEE REMARKS | Sell | 3,830 | $82.76 | $317.0K | 0 |
| Jun 24, 2025 | Hirano Patricia C | SEE REMARKS | Sell | 266 | $84.25 | $22.4K | 0 |
| Apr 1, 2025 | Hirano Patricia C | SEE REMARKS | Sell | 3,782 | $70.11 | $265.2K | 0 |
| Mar 28, 2025 | Pauls Matthew | Director | Sell | 5,937 | $71.55 | $424.8K | 0 |
| Mar 27, 2025 | Anish Bhatnagar | CHIEF EXECUTIVE OFFICER | Sell | 699,095 | $67.62 | $47.27M1.3% OS | 0 |
| Mar 27, 2025 | Hirano Patricia C | SEE REMARKS | Sell | 156,315 | $68.51 | $10.71M | 0 |
| Mar 27, 2025 | Huang Michael F. | Sr. VP of Clinical Development | Sell | 14,583 | $69.51 | $1.01M | 0 |
| Mar 27, 2025 | Mackaness James H | CHIEF FINANCIAL OFFICER | Sell | 90,622 | $69.44 | $6.29M | 0 |
| Mar 27, 2025 | Manning Meredith | Chief Commercial Officer | Sell | 45,249 | $67.28 | $3.04M | 0 |
| Mar 27, 2025 | Yen Kristen | SEE REMARKS | Sell | 95,500 | $66.77 | $6.38M | 0 |
| Jan 6, 2025 | Anish Bhatnagar | CHIEF EXECUTIVE OFFICER | Sell | 21,091 | $45.78 | $965.5K | 709,476 |
| Jan 6, 2025 | Hirano Patricia C | SEE REMARKS | Sell | 3,030 | $45.78 | $138.7K | 107,485 |
| Jan 6, 2025 | Mackaness James H | CHIEF FINANCIAL OFFICER | Sell | 7,874 | $45.78 | $360.5K | 115,410 |
| Jan 6, 2025 | Yen Kristen | SEE REMARKS | Sell | 4,860 | $45.78 | $222.5K | 79,143 |
| Oct 3, 2024 | Anish Bhatnagar | CHIEF EXECUTIVE OFFICER | Sell | 21,633 | $49.43 | $1.07M | 721,773 |
| Oct 3, 2024 | Hirano Patricia C | SEE REMARKS | Sell | 3,108 | $49.43 | $153.6K | 109,251 |
| Oct 3, 2024 | Mackaness James H | CHIEF FINANCIAL OFFICER | Sell | 8,077 | $49.43 | $399.2K | 120,001 |
| Oct 3, 2024 | Yen Kristen | SEE REMARKS | Sell | 3,108 | $49.43 | $153.6K | 81,784 |
| Aug 30, 2024 | Anish Bhatnagar | CHIEF EXECUTIVE OFFICER | Sell | 115,004 | $47.43 | $5.45M | 825,928 |
| Aug 30, 2024 | Hirano Patricia C | SEE REMARKS | Sell | 10,705 | $47.43 | $507.7K | 119,928 |
| Aug 30, 2024 | Mackaness James H | CHIEF FINANCIAL OFFICER | Sell | 13,531 | $47.43 | $641.8K | 137,219 |
| Aug 30, 2024 | Yen Kristen | SEE REMARKS | Sell | 10,705 | $47.43 | $507.7K | 92,461 |
| Aug 29, 2024 | Vivo Opportunity, LLC | 10% Owner | Sell | 1,025,000 | $48.01 | $49.21M1.9% OS | 6,816,851 |
| Aug 7, 2024 | Anish Bhatnagar | CHIEF EXECUTIVE OFFICER | Sell | 127,344 | $45.60 | $5.81M | 950,745 |
| Aug 7, 2024 | Hirano Patricia C | SEE REMARKS | Sell | 11,009 | $45.60 | $502.0K | 130,920 |
| Aug 7, 2024 | Mackaness James H | CHIEF FINANCIAL OFFICER | Sell | 14,983 | $45.60 | $683.2K | 151,905 |
| Aug 7, 2024 | Yen Kristen | SEE REMARKS | Sell | 10,974 | $45.60 | $500.4K | 103,426 |
| Jul 3, 2024 | Anish Bhatnagar | CHIEF EXECUTIVE OFFICER | Sell | 19,256 | $41.54 | $799.8K | 148,592 |
| Jul 3, 2024 | Hirano Patricia C | SEE REMARKS | Sell | 2,170 | $41.54 | $90.1K | 50,451 |
| Jul 3, 2024 | Mackaness James H | CHIEF FINANCIAL OFFICER | Sell | 7,190 | $41.54 | $298.7K | 61,385 |
| Jul 3, 2024 | Yen Kristen | SEE REMARKS | Sell | 2,170 | $41.54 | $90.1K | 22,949 |
| May 1, 2024 | Vivo Opportunity, LLC | 10% Owner | Sell | 1,101,242 | $46.95 | $51.70M2.1% OS | 7,668,093 |
| Apr 3, 2024 | Anish Bhatnagar | CHIEF EXECUTIVE OFFICER | Sell | 18,980 | $41.34 | $784.6K | 160,387 |
| Apr 3, 2024 | Hirano Patricia C | SEE REMARKS | Sell | 2,218 | $41.34 | $91.7K | 50,924 |
| Apr 3, 2024 | Mackaness James H | CHIEF FINANCIAL OFFICER | Sell | 5,175 | $41.34 | $213.9K | 65,024 |
| Apr 3, 2024 | Yen Kristen | SEE REMARKS | Sell | 2,218 | $41.34 | $91.7K | 24,310 |
| Jan 29, 2024 | Anish Bhatnagar | CHIEF EXECUTIVE OFFICER | Sell | 2,527 | $48.30 | $122.1K | 171,770 |
| Jan 29, 2024 | Hirano Patricia C | SEE REMARKS | Sell | 832 | $48.30 | $40.2K | 43,142 |
| Jan 29, 2024 | Yen Kristen | SEE REMARKS | Sell | 397 | $48.30 | $19.2K | 25,640 |
| Dec 15, 2023 | Hirano Patricia C | See Remarks | Sell | 6,244 | $38.29 | $239.1K | 21,333 |
| Dec 14, 2023 | Yen Kristen | See Remarks | Sell | 37,829 | $37.34 | $1.41M | 18,321-67% |
| Dec 13, 2023 | Anish Bhatnagar | Chief Executive Officer | Sell | 93,408 | $35.67 | $3.33M | 66,500-58% |
| Dec 13, 2023 | Mackaness James H | Chief Financial Officer | Sell | 32,482 | $36.41 | $1.18M | 38,358-46% |
SLNO Insiders
Similar Stocks to SLNO
VRTX
Vertex Pharmaceuticals Incorporated
$429.47+0.81%
$111.71B
REGN
Regeneron Pharmaceuticals, Inc.
$734.06-1.39%
$77.87B
ALNY
Alnylam Pharmaceuticals, Inc.
$303.44-1.64%
$41.24B
INSM
Insmed Incorporated
$135.11-0.64%
$30.79B
RVMD
Revolution Medicines, Inc.
$144.62+9.92%
$29.51B
UTHR
United Therapeutics Corporation
$566.69+0.03%
$25.13B
MRNA
Moderna, Inc.
$47.16-3.17%
$21.42B
RPRX
Royalty Pharma plc
$49.40-0.50%
$21.20B